ZGNX earnings

Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced U.S. Food and Drug Administration acceptance with Priority Review of Supplemental New Drug Application for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Submitted Type II Variation Application to the European Medicines Agency to expand the use of FINTEPLA for LGSSubmitted New Drug Application to Japan's Ministry of Health, Labour & Welfare for the marketing approval of FINTEPLA in Dravet syndromePreviously announced agreement to be acquired by UCB; transaction expected to close in the first half of

BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ:ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of US$ 26.00 in cash at closing, plus a contingent value right (CVR) for a potential cash payment of US$ 2.00 upon EU approval by December 31, 2023, of FINTEPLA® as an orphan medicine fo

FINTEPLA® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectivelySubmitted supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Continuing to advance late-stage development programs for FINTEPLA and MT1621 EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced financial results for the three and nine months ended September 30, 2021, and provided a corporate update. The Company will host a conferen

EMERYVILLE, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, November 4, 2021, at 4:30 PM Eastern Time. Conference Call Details Thursday, November 4, at 4:30 PM Eastern Time / 1:30 PM Pacific TimeToll Free:855-327-6838International:604-235-2082Conference ID:10016695Webcast:http://public.viavid.com/index.php?id=146849  About Zogenix Zogenix is a global biopharmaceutical company committed to developing and co

Commercial launches of FINTEPLA® in the U.S. and Europe progressing strongly, with total net product sales of $17.5 million and total revenue of $18.8 million in the second quarter, representing quarter-over-quarter increases of 42% and 37%, respectivelyAs of June 30, 2021, over 860 patients have been prescribed FINTEPLA and referred to the REMS program, and there were 290 unique prescribers, an increase of 22% quarter-over-quarter On track to submit supplemental New Drug Application (NDA) seeking to expand FINTEPLA's label for treatment of Lennox-Gastaut syndrome (LGS) in Q3 2021, following positive meeting with U.S. Food and Drug Administration (FDA)Anticipate NDA submission for MT1621 in

EMERYVILLE, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will report its financial results for the second quarter ended June 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, August 5, 2021, at 4:30 PM Eastern Time. Conference Call DetailsThursday, August 5, at 4:30 PM Eastern Time / 1:30 PM Pacific TimeToll Free:                800-347-6311International:                323-994-2131Conference ID:        6229003Webcast:                http://public.viavid.com/index.php?id=145894 About ZogenixZogenix is a glob